EGFR and neoplasm: For patients with systemic progression and a confirmed T790M mutation either with tissue biopsy or circulating-tumor DNA (ctDNA) plasma testing (and tissue re-biopsy if plasma test is negative), administration of the third generation EGFR-TKI, osimertinib, is the treatment of choice, while for patients who cannot undergo tissue biopsy or for whom a T790M mutation is not detected, the contemporary ESMO guidelines recommend switching to platinum-based chemotherapy [3,25,26].